Market Overview

The global dermatological drugs market in terms of revenue was estimated to be worth USD 42.41 Billion in 2023 and is poised to reach USD 88.08 Billion by 2032, growing at a CAGR of 8.5 % from 2024 to 2032.

The dermatological drugs market is the global market for pharmaceutical goods created especially to treat skin-related disorders. In this market, there are several medications available, which are designed to address conditions like rosacea, psoriasis, eczema, acne, skin infections, and other dermatological conditions. Among the several types of dermatological drugs include topical creams, ointments, gels, oral pills, and injectable.

Trapping of microorganisms, parasites, fungi, and the other forms of microorganisms dwelling inside the skin pores as well as hair follicles; failure to hold moisture; preventing dehydration; increase in the levels of pollutants are some of the driving factors in the dermatological medicine industry around the globe. Other than that, the dermatological drugs market is expanding because of high demand for speedy diagnosis, increased consciousness about skin infections. With the growing expenditures in R&D to develop new medicines and the ever-growing demand for advanced medicines, the market revenue will grow.

Several governments enforced lockdowns, which restricted the physical mobility of people. Therefore, everyone stayed at home out of caution. Oncology medicine supply chains were disturbed. Since the dermatological drugs are under urgent and exigent conditions, the normal drug supply is allowed in this situation. Consequently, the pandemic has minimal effect on market income.

Dermatology is that branch of medicine that consists of the identification, management, and prevention of diseases involving the skin, hair, and nails. Drugs prescribed for the treatment of disorders related to the skin are called dermatological drugs. Dermatological drugs avert the disease from occurring in the skin. Various forms of dermatological drugs are laser therapy, topical and systemic drugs, photodynamic therapy, radiation, vitiligo surgery, and dermatological surgery. These drugs also find an application in dermatology with a purpose of healthy and young-looking skin.

Increased elderly population, increased knowledge about the skin condition, increased spending capacity, and abundant availability of dermatological drugs, this market segment is expected to grow at a rapid pace during the forecast period. Another major factor that is responsible for the growth of the dermatological drug market is the increased prevalence of skin disorders. Stress, dietary habits, hereditary and environmental causes, and age are among the most significant causes of skin diseases in millions of people worldwide. Skin disease is the most common group of diseases that affect over 900 million people globally at a given time. According to a report presented by the World Health Organization, treatment efforts on skin dermatological diseases notwithstanding, there is a need for developing inexpensive and therapeutically effective drugs. Pharmaceutical companies are manufacturing drugs for dermatological diseases because of increasing prevalence of atopic dermatitis (eczema), acne infections, and other diseases in the general population. Research and development costs are increasing for the companies. For example, Alembic Pharmaceuticals’ topical retinoid Adapalene Gel USP 0.3% for acne vulgaris in patients aged 12 years and above has been approved by the FDA in 2020.

This has been due to several government and private sector initiatives that increase the pharmaceutical industry. Moreover, the market is also increasing with increased approvals in the dermatology product portfolio. For example, the pharmaceutical company AbbVie Inc. said in December 2021 that the FDA approved its Rinvoq (upadacitinib) to treat patients suffering from active psoriatic arthritis. However, availability of alternative treatments for acne, chemical peels, light or laser therapy, micro needling, microdermabrasion, and lesion removal, is likely to further restrain the dermatology market growth over the duration of the forecast period.

Key Findings

• Pfizer Inc. declared in June 2023 that the US FDA had authorized LITFULO (ritlecitinib), a novel oral medication for people with severe alopecia areata who are 12 years of age or older.
• The U.S. FDA approved Bristol Myers Squibb's oral medication, Sotyktu, in September 2022 for the treatment of moderate-to-severe plaque psoriasis.
• Amazon opened an online pharmacy in the United States in November 2020. The pharmacy offered both prescription and generic pharmaceuticals to its customers.
• In order to develop, produce, and market a topical solution called roflumilast in Greater China and Southeast Asia, Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly owned subsidiary of Huadong Medicine Co., Ltd., announced a strategic partnership and licensing agreement in August 2023.
• To increase their immunology pipeline, Eli Lilly and Company announced in June 2023 that they had struck a deal to purchase DICE Therapeutics, Inc.

Market Drivers

• Growing Awareness and Demand for Aesthetic Treatments

The demand for dermatological products has increased enormously and extends beyond traditional health care to cosmetic and aesthetic uses. Consumers' growing concern about the health and look of their skin is pushing demand for products that enhance beauty and manage age-related changes in the skin. Since more individuals are searching for non-invasive means to maintain a young appearance for the skin, many have been searching for help in anti-aging treatments. These include such serums and lotions that were meant to eliminate fine lines and wrinkles. Solutions meant to treat issues of pigmentation such as dark spots and uneven tone attract a huge audience cut across ages and skin types.

The growth is driven primarily by increased knowledge of the importance of skincare for general health and beauty, alongside developments in dermatological research with more affordable and efficient products. Many individuals prioritize aesthetic skincare as a result of the strong social media influence and the significant role of beauty influencers who promote products. The market for dermatology is, therefore growing rapidly, as therapies become combined for better health of skin that have both scientific underpinnings and aesthetical appeal.

Key Findings

• The National Institute of Allergy and Infectious Disease (NIAID) awarded ResVita Bio a USD 250,000 phase 1 Small Business Innovation Research (SBIR) grant in September 2023 to help research a new treatment for severe Atopic Dermatitis (AD).
• The U.S. FDA gave AbbVie, Inc. permission to use Rinvoq to treat severe atopic dermatitis in patients 12 years of age and older in January 2022.

Market Opportunities

• Technological Innovations and Biologic Drugs

Advancements in biotechnology with developments such as biologic drugs and targeted therapy changed the course of treatment directed to chronic and complicated skin conditions such as atopic dermatitis and severe psoriasis. Biologics refers to medications derived from organisms and thus have a drug mechanism based on their interference through their capability to zero-in at some specific constituents in the immune system that contributes to inflammation. Due to its capability to zero at specific parts of the immune system, biologics give better and efficient control in controlling the symptoms without inducing unwanted adverse effects than traditionally established treatments.

Indeed, biologics have very good effectiveness in treating the so-called untreatable diseases of the skin and improvement of the quality of life for patients for a long time. Most of the biologics were made to block particular cytokines or immunologic pathways, which induce inflammation, thereby causing significant clearance of the skin and sustained control of the symptoms in case of psoriasis.

These developments are bringing growth opportunities, particularly to areas where few treatment alternatives exist. These advanced drugs shall find their markets in developing regions with expanded global healthcare access, which will serve an unmet demand for safer and more effective treatments of debilitating skin conditions.

Market Restraining Factors

• Availability of Alternative Therapies

Prescription dermatological drugs have been influenced by the increased use of natural remedies, cosmetic treatments, and over-the-counter drugs, primarily in the management of benign skin conditions. Since they can be accessed from pharmacies, supermarkets, and internet-based retailers, are not provided by prescription, most clients have found them more accessible and convenient to acquire. For those people that want to treat minor ailments such as acne, tiny rashes, or just dry skin without consulting with a physician, over the counter treatments are very tempting mainly because they are often significantly cheaper than prescription medications.

More demand for natural remedies exists because of comprehensive skincare requirements from customers. These consist of serums of plant origin, essential oils, and herbal creams that are attracting health-conscious customers because they usually claim to be safer and chemical-free. Visible cosmetic treatments consist of correctors for pigmentation and anti-aging creams that attract more customers who demand them nowadays than ever before.

The demand for dermatological drugs is likely to decline due to the inclination of the patients toward cheaper or alternative treatments, especially in minor skin ailments.

Segmentation Analysis

The market scope is segmented because of by Treatment Type, by Drug Class, by Route of Administration, by Distribution Channel.

• By Treatment Type

Based on the Treatment Type of the market is segmented into Acne, Psoriasis, Dermatitis/Eczema, Skin Infections, Rosacea, Alopecia, Other Disorders.

Acne treatments lead market share because of the high prevalence of acne, especially in adolescents and young adults. The products like benzoyl peroxide, salicylic acid, retinoid reduce inflammation, pour blockages, and decrease oil production is used in controlling symptoms or preventing a breakout in acne medications and treatments. Another area is psoriasis, with emphasis on chronic cases where biologic drugs such as ustekinumab and adalimumab may become necessary because these interact directly with the immune system in order to modulate and decrease attacks of symptoms.

No steroidal topical treatments and corticosteroids are administered to treat both dermatitis and eczema on a regular basis as part of the treatment process to manage inflammation and itch. Antibiotics and antifungals are administered for bacterial, viral, and fungal infections, such as terbinafine to address fungal problems and mupirocin for bacterial infection. Monoxide and finasteride cause hair growth, whereas metronidazole and azelaic acid are treatments for rosacea that lessen redness and inflammation. Lastly, it offers treatments for skin cancers and pigmentation problems, among other skin issues. Hydroquinone creams for instance are very commonly applied to lighten hyperpigmentation, offering localized therapy to many dermatomes.

• By Drug Class

Based on the Drug Class of the market is segmented into Anti-inflammatory, Anti-bacterial and Anti-fungal, Retinoid, Calcineurin Inhibitors, Biologics, Others.

Anti-inflammatory drugs comprise the majority of dermatological drugs because inflammation is among the most prominent symptoms of many skin diseases. In dermatitis, psoriasis, and eczema, the doctors give them corticosteroids which are one of the commonly used anti-inflammatory medicines to lessen swelling, redness, and itching. Although they use NSAIDs for management of inflammation in mild conditions, they are not frequently prescribed for diseases of the skin.

Antibacterial and antifungal drugs can treat such infections on the skin. Antibiotics such as mupirocin act by eradicating the pathogens, while clotrimazole acts on the fungi to kill them. Retinoid therapy is mainly given for acne and anti-aging by suppressing sebum production and by increasing cellular turnover to open pores and refreshing the skin. Calneuorin inhibitors such as tacrolimus also used instead of steroids with maintaining the control of immune-related reactions in atopic dermatitis without thinning down the skin. In all cases of autoimmune-based eczema like acute attack of psoriasis, biological agents are the newer options of treatment. Like a way to prevent flare, there is a drug such as adalimumab; it works by halting the pathway of an immunity system. Some medicines treat the needs. Other related medicines are immunosuppressant and antihistamines. For instance, antihistamines could be used for combating reaction to allergic factors affecting your skin.

• Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. The United States, in the North American region, accounts for the largest market of dermatological drugs. High levels of health care infrastructures combined with increasing disposable incomes and the growing need for skin health and aesthetic concerns underpin the growth in the market. Strong pipelines from major pharmaceutical companies developing innovative biologics and targeted therapies are also underpinning growth in this region. The most prevalent conditions are acne, psoriasis, and eczema, all of which require treatment. Preventive skincare is the new buzz in this region, combined with cosmetic dermatology, which helps increase the market's growth.

The other major market is Europe, which is heavily focused on research and development of dermatological products. Advanced therapies such as biologics and novel topical treatments are more and more taken up in Germany, France, and the UK. Another driving factor of the European market is increased awareness of skin diseases and an aging population that creates a greater demand for anti-aging products. In Europe, the European Medicines Agency ensures safe and effective dermatological drugs and supports the growth of this market.

The Asia-Pacific region is the most rapidly growing market for dermatological drugs, with growth driven by increased disposable incomes, better access to healthcare, and growing awareness of skin health. Countries like China, India, and Japan contribute significantly to this growth. Increased incidence of skin conditions due to urbanization, pollution, and lifestyle changes further fuels demand. More and more middle-class populations are spending more on skincare products, whether therapeutic or cosmetic. The young population of the region also increases the demand for acne treatments and aesthetic procedures, making it a very lucrative market for manufacturing companies that offer dermatological drugs.

With these challenges of economic instability, limited access to health care in some areas, etc., dermatological drugs are expanding their market in Latin America. Brazil and Mexico, the key markets, witness increased awareness on dermatological conditions and high demand for cosmetic treatments. The E-commerce is also developing the access to dermatological products, which is further causing a growth in the market region.

There are promising growth prospects in the Middle East and Africa region, which is also associated with the increase in health care investments and the spread of knowledge about the presence of dermatological conditions. The market is also increasingly characterized by the prevalence of skin disorders due to environmental factors and lifestyle changes. However, there are still challenges in terms of accessibility to advanced treatments and variation in regulatory standards.

The dermatological drugs market is quite diversified. North America and Europe dominate revenue, though Asia-Pacific is promising to offer huge growth opportunities due to both surging demand and changes in healthcare setups.

List of Companies Profiled

• Novartis AG
• Amgen Inc
• AbbVie Inc
• Johnson & Johnson
• Leo Pharma A/S
• Eli Lilly and Company
• GlaxoSmithKline Plc
• AstraZeneca plc
• Pfizer Inc
• Merck KGaA.

Key Industry Developments

• Novartis AG declared in April 2023 that Cosentyx (secukinumab) had been approved for commercialization by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to treat patients with active moderate-to-severe Hidradenitis Suppurativa (HS).
• According to LEO Pharma, Adbry (tralokinumab-ldrm), which was approved by the U.S. FDA in December 2021, is the first and only medication for people with moderate-to-severe atopic dermatitis that targets IL-13 directly.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Dermatological Drugs Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Dermatological Drugs market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Dermatological Drugs. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Dermatological Drugs companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Dermatological Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Dermatological Drugs Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Dermatological Drugs Market valued?
• Which region has the largest share in 2024 for the global Dermatological Drugs Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of the Market

• Historic year: 2019-2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Million

Dermatological Drugs Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: